PVLA
NasdaqPalvella Therapeutics, Inc.
Basic Materials · Pharmaceutical Preparations
Research view
Fundamentals · SEC EDGAR · FY 2023-12-31
Revenue & Earnings — fiscal year
$32.1M
2019
$23.9M
2020
$27.9M
2021
$25.5M
2022
$38.7M
2023
Snapshot
SEC EDGAR · FY 2023-12-31Revenue$38.7M
Net Income$18.7M
Gross Profit—
Oper Income$-38.6M
EPS (dil)$-3.71
Rev/sh$2.70
FCF/sh$-1.76
Book/sh$-5.19
Gross M—
Oper M-99.7%
Profit M48.3%
FCF M-65.0%
ROE-25.1%
ROA247.6%
ROIC—
R&D/Rev59.0%
Rev Y/Y52.0%
Rev 3Y CAGR17.4%
EPS Y/Y52.6%
EPS 3Y CAGR—
FCF 3Y CAGR—
Payout—
Div/sh—
Shs Chg Y/Y+405.5%
Current Ratio3.20
Quick Ratio—
Debt/Eq—
Int Coverage-14.5×
Net Debt—
Total Debt—
Cash & Eq$7.3M
Total Assets$7.5M
Oper CF$-25.0M
Capex$171,000
Free CF$-25.2M
Buybacks—
Equity$-74.5M
Liabilities$11.4M
Shs Outstand0.01B
SectorBasic Materials
🔒 P/E—
🔒 Fwd P/E—
🔒 P/S—
🔒 P/B—
🔒 Market Cap—
🔒 Div Yield—
🔒 52W Range—
🔒 Beta—
40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.
Financials — annual
SEC EDGAR · last 5 FY| USD | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|
| Revenue | $32.1M | $23.9M | $27.9M | $25.5M | $38.7M |
| Gross Profit | — | — | — | — | — |
| Operating Income | $-27.2M | $-33.9M | $-51.8M | $-43.5M | $-11.9M |
| Net Income | $-25.5M | $-37.2M | $-45.7M | $-33.3M | $18.7M |
| Diluted EPS | $-0.56 | $-0.68 | $-0.71 | — | $2.17 |
| Operating Cash Flow | $-52.5M | $-45.9M | $-7.7M | $-59.9M | $-13.7M |
| Free Cash Flow | $-54.9M | $-48.6M | $-8.6M | $-61.0M | $-13.9M |
COMMUNITY · $PVLA0 theses
POST YOUR TAKE →Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.